GLP-1 (7–36) amide vs Oxyntomodulin

How they're alike

GLP-1 (7–36) amide and oxyntomodulin are sibling products of the same gene. Both are cleaved from the proglucagon precursor by prohormone convertase 1/3 in intestinal L-cells and are co-secreted into the bloodstream after a meal, alongside GLP-2 and glicentin (Lafferty 2021, Gasbjerg 2026). Both bind and activate the GLP-1 receptor — a class B G-protein-coupled receptor on pancreatic β-cells, gut, and appetite-regulating brain neurons — to produce overlapping incretin and satiety effects, including glucose-dependent insulin release, suppression of glucagon, slowed gastric emptying, and reduced food intake (Donnelly 2012, Graaf 2016, Farhadipour 2021). Both are also pharmacologically fragile: short circulating half-lives in vivo mean that neither native peptide is itself a marketed therapeutic, and both have instead served as templates for engineered analogs (Graaf 2016, Pocai 2014).

How they differ

The decisive difference is receptor selectivity. GLP-1 (7–36) amide is a 30-residue, C-terminally amidated peptide that is selective for GLP-1R; its physiology is the canonical incretin axis (Donnelly 2012, Graaf 2016). Oxyntomodulin is 37 residues — the full 29-amino-acid glucagon sequence extended by an 8-residue C-terminal tail from the proglucagon IP-1 region — and is a free-acid peptide that activates GLP-1R and the glucagon receptor (GCGR) at roughly 10–100-fold lower potency than the selective endogenous agonist at each site (Pocai 2014, Lafferty 2021). A BLOSUM62 local alignment between the two peptides shows 50% identity across the 30-residue overlap, reflecting deep shared ancestry within the proglucagon precursor.

The pharmacological consequence of that extra receptor arm is what distinguishes oxyntomodulin physiologically: GCGR activation adds glucagon-like effects — increased energy expenditure and lipolysis — on top of the GLP-1R-mediated satiety and incretin actions (Scott 2018, Pocai 2014). Human infusion work has further shown that native oxyntomodulin has glucoregulatory effects that are independent of its weight-loss effects (Shankar 2018), reinforcing that its dual-receptor profile produces a different overall signature than selective GLP-1R activation. By contrast, GLP-1 (7–36) amide carries no appreciable GCGR activity; its therapeutic descendants (semaglutide, liraglutide, exenatide, tirzepatide) are likewise built on receptor-selective scaffolds, with tirzepatide being a GLP-1R/GIPR dual agonist rather than a GLP-1R/GCGR one (Graaf 2016, Galindo 2026). The other meaningful mechanistic difference is at the C-terminus: GLP-1's C-terminal amide is part of its receptor pharmacophore at GLP-1R and is invisible in the bare letter sequence (Donnelly 2012), while oxyntomodulin's free-acid C-terminal extension is the structural feature that confers its GCGR co-activity and distinguishes it from glucagon(1-29) (Pocai 2014).

Head-to-head clinical evidence

No head-to-head clinical trial directly comparing native GLP-1 (7–36) amide with native oxyntomodulin appears in the dossier; the dedicated PubMed search for trials naming both peptides returned no candidates. This is consistent with the development status of each peptide — neither has been advanced as a marketed drug, and both are studied primarily as physiological probes or as scaffolds for engineered analogs (Graaf 2016, Pocai 2014). The closest available comparative evidence is mechanistic and inferential rather than trial-based. Salehi and colleagues used the GLP-1R antagonist exendin-(9–39) to isolate the contribution of endogenous GLP-1 to post-prandial insulin secretion in people with and without type 2 diabetes, showing that endogenous GLP-1 accounts for a meaningful share of the incretin response (Salehi 2010); together with the broader incretin-effect literature, this anchors GLP-1's quantitative role at GLP-1R (Seino 2010). On the oxyntomodulin side, Dakin and colleagues showed that peripheral oxyntomodulin inhibits food intake in the rat (Dakin 2001), and subsequent human work demonstrated glucoregulatory and energy-expenditure effects attributable in part to the GCGR arm of the dual-agonist profile (Shankar 2018, Scott 2018). Readers should treat any cross-peptide comparison here as a contrast between two physiological signatures rather than as a clinical efficacy ranking.

Safety profile comparison

Neither native peptide has the kind of large-scale safety database that approved GLP-1 analogs have accumulated; both have been studied chiefly in short infusions or small mechanistic cohorts. For GLP-1 (7–36) amide, the available human data come from incretin-physiology studies and receptor-antagonism work in which the peptide or its blocker has been infused acutely without major reported adverse events (Kreymann 1987, Salehi 2010). The pharmacological liability of native GLP-1 is not toxicity but pharmacokinetic — rapid cleavage between Ala8 and Glu9 by dipeptidyl peptidase-4 abolishes receptor activity within minutes (Graaf 2016), which is why the marketed drug class is built on DPP-4–resistant analogs rather than the native sequence. For oxyntomodulin, the small human exposure data summarized in the Pocai (2014) review and the Shankar (2018) infusion study likewise did not flag major adverse signals, and the dossier records no boxed warning or unique safety event for native OXM. Where safety considerations bite is in the engineered drug class downstream of each peptide, which is outside the scope of this native-peptide comparison.

Indication overview

GLP-1 (7–36) amide as a native peptide is not marketed in the US or EU; its clinical footprint is entirely indirect, through the engineered GLP-1 analog drug class — semaglutide, liraglutide, exenatide, and tirzepatide — that targets type 2 diabetes and obesity by reproducing GLP-1R pharmacology on a longer timescale (Graaf 2016, Galindo 2026). Oxyntomodulin similarly has no approved clinical use as the native peptide; its pharmacological role is as the natural prototype for the GLP-1R/GCGR co-agonist drug class, with synthetic co-agonists in active late-stage development for obesity (Pocai 2014, Lafferty 2021). Both peptides therefore occupy the same position in the regulatory landscape — research-grade biological reference ligands rather than therapeutics — while their respective drug classes occupy different segments of the metabolic-disease market.